Old Port Advisors Decreases Holdings in Moderna, Inc. (NASDAQ:MRNA)

Old Port Advisors trimmed its holdings in Moderna, Inc. (NASDAQ:MRNA) by 1.8% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 13,186 shares of the company’s stock after selling 247 shares during the quarter. Old Port Advisors’ holdings in Moderna were worth $881,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in MRNA. Vanguard Group Inc. raised its position in Moderna by 15.1% in the 1st quarter. Vanguard Group Inc. now owns 39,036,872 shares of the company’s stock worth $4,159,769,000 after purchasing an additional 5,129,800 shares during the period. Sumitomo Mitsui Trust Holdings Inc. grew its stake in shares of Moderna by 42.9% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,545,829 shares of the company’s stock valued at $164,724,000 after buying an additional 463,960 shares during the last quarter. Nikko Asset Management Americas Inc. grew its stake in shares of Moderna by 156.9% during the first quarter. Nikko Asset Management Americas Inc. now owns 741,783 shares of the company’s stock valued at $79,044,000 after buying an additional 453,004 shares during the last quarter. International Assets Investment Management LLC increased its holdings in shares of Moderna by 10,687.1% in the third quarter. International Assets Investment Management LLC now owns 319,514 shares of the company’s stock worth $21,353,000 after buying an additional 316,552 shares during the period. Finally, Intech Investment Management LLC lifted its stake in shares of Moderna by 1,212.9% in the 1st quarter. Intech Investment Management LLC now owns 330,805 shares of the company’s stock valued at $35,251,000 after acquiring an additional 305,609 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Stock Performance

Shares of Moderna stock opened at $54.80 on Tuesday. Moderna, Inc. has a 12 month low of $52.26 and a 12 month high of $170.47. The firm has a market capitalization of $21.00 billion, a P/E ratio of -3.50 and a beta of 1.66. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05. The business has a fifty day simple moving average of $67.68 and a two-hundred day simple moving average of $102.74.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.47) by $0.14. The company had revenue of $241.00 million during the quarter, compared to analysts’ expectations of $128.41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. Moderna’s revenue was down 29.9% on a year-over-year basis. During the same period last year, the company posted ($3.62) EPS. On average, equities analysts forecast that Moderna, Inc. will post -9.88 earnings per share for the current fiscal year.

Insider Transactions at Moderna

In related news, CFO James M. Mock sold 1,321 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the transaction, the chief financial officer now owns 8,600 shares of the company’s stock, valued at $682,754. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Moderna news, CFO James M. Mock sold 715 shares of Moderna stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the transaction, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO James M. Mock sold 1,321 shares of the stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the sale, the chief financial officer now owns 8,600 shares in the company, valued at approximately $682,754. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 18,184 shares of company stock valued at $2,037,931 in the last ninety days. 15.70% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on MRNA. Hsbc Global Res upgraded Moderna from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 28th. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research note on Friday, September 13th. Sanford C. Bernstein began coverage on shares of Moderna in a report on Thursday, October 17th. They set a “market perform” rating and a $55.00 price target for the company. Oppenheimer lowered shares of Moderna from an “outperform” rating to a “market perform” rating in a report on Friday, September 13th. Finally, Bank of America lowered their price objective on shares of Moderna from $130.00 to $110.00 and set a “neutral” rating for the company in a research note on Friday, September 13th. Two equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $94.65.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.